Compositions and methods for the treatment of inflammatory bowel disease

Patent metadata

Field	Value
Publication number	US-9498461-B2
Application number	US-201314533111-A
Country	US
Kind code	B2
Filing date	May 15, 2013
Priority date	May 23, 2012
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

First claim

What is claimed is:

1. A compound of:

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, enantiomer, or stereoisomer thereof.

2. A compound of:

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, prodrug, enantiomer, or stereoisomer thereof.

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

5. A pharmaceutical composition of claim 3 , further comprising a molecular conjugate of mesalazine, caprylic acid and carboxylic compounds selected form a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

6. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is eicosapentaenoic acid.

7. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is docosahexaenoic acid.

8. A pharmaceutical composition of claim 4 , further comprising a molecular conjugate of, caprylic acid and a compound selected form a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

9. The pharmaceutical composition of claim 8 , wherein the carboxylic acid compound is eicosapentaenoic acid.

10. The pharmaceutical composition of claim 8 , wherein the carboxylic acid compound is docosahexaenoic acid.

Assignees

• Kandula Mahesh
• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title